Compare TG Therapeutics Inc (TGTX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Upwork Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: TG Therapeutics Inc is far larger — about 7.6× Upwork Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Upwork Inc for 38 Days on average.
| TGTX | UPWK | |
|---|---|---|
Market Cap | $8.16B | $1.07B |
Volume | 1,735,121 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $59.06 | $22.11 |
52-Week Low | $26.94 | $7.84 |
Typical Hold Time | 16 Days | 38 Days |
Enterprise Value | $8.37B | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
UPWK trades at $8.57, up 2.02% today, with a bearish technical signal from moving averages and RSI near overbought levels. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing on revenue guidance, leading to a recent stock decline. Fundamentals show strong profitability with a 77.21% gross margin and 12.93% net income margin, while valuation ratios like P/E of 10.99 and P/S of 1.48 appear reasonable. Recent news highlights insider selling and ongoing securities fraud investigations.
The outlook for UPWK is cautious due to AI-driven competitive threats and weak guidance, though low valuation provides downside protection. Risks include declining active clients and legal scrutiny, but analyst consensus remains bullish with a $9.64 price target. Investment opportunity hinges on execution amid industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
